From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

Melanoma currently lacks a reliable blood‐based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or...

Full description

Bibliographic Details
Main Authors: Steven P. Rowe, Brandon Luber, Monique Makell, Patricia Brothers, JoAnn Santmyer, Megan D. Schollenberger, Hannah Quinn, Daniel L. Edelstein, Frederick S. Jones, Karen B. Bleich, William H. Sharfman, Evan J. Lipson
Format: Article
Language:English
Published: Wiley 2018-10-01
Series:Molecular Oncology
Subjects:
circulating tumor DNA
ctDNA
melanoma
Online Access:https://doi.org/10.1002/1878-0261.12373

Internet

https://doi.org/10.1002/1878-0261.12373

Similar Items